Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial

Jagdeep S. S. Singh; Ify R. Mordi; Keeran Vickneson; Amir Fathi; Peter T. Donnan; Mohapradeep Mohan; Anna Maria J. Choy; Stephen Gandy; Jacob George; Faisel Khan; Ewan R. Pearson; J. Graeme Houston; Allan D. Struthers; Chim C. Lang

doi:10.2337/dc19-2187

Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial

Jagdeep S. S. Singh, Ify R. Mordi, Keeran Vickneson, Amir Fathi, Peter T. Donnan, Mohapradeep Mohan, Anna Maria J. Choy, Stephen Gandy, Jacob George, Faisel Khan, Ewan R. Pearson, J. Graeme Houston, Allan D. Struthers, Chim C. Lang (Lead / Corresponding author)

Research output: Contribution to journal › Article › peer-review

119 Citations (Scopus)

183 Downloads (Pure)

Abstract

Objective: To determine the effects of dapagliflozin in patients with heart failure (HF) and type 2 diabetes mellitus (T2DM) on left ventricular (LV) remodeling using cardiac MRI.

Research Design and Methods: We randomized 56 patients with T2DM and HF with LV systolic dysfunction to dapagliflozin 10 mg daily or placebo for 1 year, on top of usual therapy. The primary end point was difference in LV end-systolic volume (LVESV) using cardiac MRI. Key secondary end points included other measures of LV remodeling and clinical and biochemical parameters.

Results: In our cohort, dapagliflozin had no effect on LVESV or any other parameter of LV remodeling. However, it reduced diastolic blood pressure and loop diuretic requirements while increasing hemoglobin, hematocrit, and ketone bodies. There was a trend toward lower weight.

Conclusion: We were unable to determine with certainty whether dapagliflozin in patients with T2DMand HF had any effect on LV remodeling.Whether the benefits of dapagliflozin in HF are due to remodeling or other mechanisms remains unknown.

Original language	English
Pages (from-to)	1356-1359
Number of pages	4
Journal	Diabetes Care
Volume	43
Issue number	6
Early online date	3 Apr 2020
DOIs	https://doi.org/10.2337/dc19-2187
Publication status	Published - 1 Jun 2020

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Advanced and Specialised Nursing

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2337/dc19-2187

Author Accepted ManuscriptAccepted author manuscript, 172 KB

Cite this

Singh, J. S. S., Mordi, I. R., Vickneson, K., Fathi, A., Donnan, P. T., Mohan, M., Choy, A. M. J., Gandy, S., George, J., Khan, F., Pearson, E. R., Houston, J. G., Struthers, A. D., & Lang, C. C. (2020). Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. Diabetes Care, 43(6), 1356-1359. https://doi.org/10.2337/dc19-2187

@article{fa714399efad457e87ca4f038c505f65,

title = "Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial",

abstract = "Objective: To determine the effects of dapagliflozin in patients with heart failure (HF) and type 2 diabetes mellitus (T2DM) on left ventricular (LV) remodeling using cardiac MRI.Research Design and Methods: We randomized 56 patients with T2DM and HF with LV systolic dysfunction to dapagliflozin 10 mg daily or placebo for 1 year, on top of usual therapy. The primary end point was difference in LV end-systolic volume (LVESV) using cardiac MRI. Key secondary end points included other measures of LV remodeling and clinical and biochemical parameters.Results: In our cohort, dapagliflozin had no effect on LVESV or any other parameter of LV remodeling. However, it reduced diastolic blood pressure and loop diuretic requirements while increasing hemoglobin, hematocrit, and ketone bodies. There was a trend toward lower weight.Conclusion: We were unable to determine with certainty whether dapagliflozin in patients with T2DMand HF had any effect on LV remodeling.Whether the benefits of dapagliflozin in HF are due to remodeling or other mechanisms remains unknown.",

author = "Singh, {Jagdeep S. S.} and Mordi, {Ify R.} and Keeran Vickneson and Amir Fathi and Donnan, {Peter T.} and Mohapradeep Mohan and Choy, {Anna Maria J.} and Stephen Gandy and Jacob George and Faisel Khan and Pearson, {Ewan R.} and Houston, {J. Graeme} and Struthers, {Allan D.} and Lang, {Chim C.}",

note = "This study was funded by a grant fromthe European Foundation for the Study of Di-abetes, Clinical Diabetes Research Programme inMacrovascular Complications of Diabetes. I.R.M.is supported by a National Health Service Edu-cation for Scotland/Chief Scientist Office Post-Doctoral Clinical Lectureship (PCL 17/07). M.M.is supported by the British Heart Foundation(grant number PG/14/4/30539).",

year = "2020",

month = jun,

day = "1",

doi = "10.2337/dc19-2187",

language = "English",

volume = "43",

pages = "1356--1359",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association Inc.",

number = "6",

}

Singh, JSS, Mordi, IR, Vickneson, K, Fathi, A, Donnan, PT, Mohan, M, Choy, AMJ, Gandy, S, George, J, Khan, F , Pearson, ER , Houston, JG , Struthers, AD & Lang, CC 2020, 'Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial', Diabetes Care, vol. 43, no. 6, pp. 1356-1359. https://doi.org/10.2337/dc19-2187

TY - JOUR

T1 - Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure

T2 - The REFORM Trial

AU - Singh, Jagdeep S. S.

AU - Mordi, Ify R.

AU - Vickneson, Keeran

AU - Fathi, Amir

AU - Donnan, Peter T.

AU - Mohan, Mohapradeep

AU - Choy, Anna Maria J.

AU - Gandy, Stephen

AU - George, Jacob

AU - Khan, Faisel

AU - Pearson, Ewan R.

AU - Houston, J. Graeme

AU - Struthers, Allan D.

AU - Lang, Chim C.

N1 - This study was funded by a grant fromthe European Foundation for the Study of Di-abetes, Clinical Diabetes Research Programme inMacrovascular Complications of Diabetes. I.R.M.is supported by a National Health Service Edu-cation for Scotland/Chief Scientist Office Post-Doctoral Clinical Lectureship (PCL 17/07). M.M.is supported by the British Heart Foundation(grant number PG/14/4/30539).

PY - 2020/6/1

Y1 - 2020/6/1

N2 - Objective: To determine the effects of dapagliflozin in patients with heart failure (HF) and type 2 diabetes mellitus (T2DM) on left ventricular (LV) remodeling using cardiac MRI.Research Design and Methods: We randomized 56 patients with T2DM and HF with LV systolic dysfunction to dapagliflozin 10 mg daily or placebo for 1 year, on top of usual therapy. The primary end point was difference in LV end-systolic volume (LVESV) using cardiac MRI. Key secondary end points included other measures of LV remodeling and clinical and biochemical parameters.Results: In our cohort, dapagliflozin had no effect on LVESV or any other parameter of LV remodeling. However, it reduced diastolic blood pressure and loop diuretic requirements while increasing hemoglobin, hematocrit, and ketone bodies. There was a trend toward lower weight.Conclusion: We were unable to determine with certainty whether dapagliflozin in patients with T2DMand HF had any effect on LV remodeling.Whether the benefits of dapagliflozin in HF are due to remodeling or other mechanisms remains unknown.

AB - Objective: To determine the effects of dapagliflozin in patients with heart failure (HF) and type 2 diabetes mellitus (T2DM) on left ventricular (LV) remodeling using cardiac MRI.Research Design and Methods: We randomized 56 patients with T2DM and HF with LV systolic dysfunction to dapagliflozin 10 mg daily or placebo for 1 year, on top of usual therapy. The primary end point was difference in LV end-systolic volume (LVESV) using cardiac MRI. Key secondary end points included other measures of LV remodeling and clinical and biochemical parameters.Results: In our cohort, dapagliflozin had no effect on LVESV or any other parameter of LV remodeling. However, it reduced diastolic blood pressure and loop diuretic requirements while increasing hemoglobin, hematocrit, and ketone bodies. There was a trend toward lower weight.Conclusion: We were unable to determine with certainty whether dapagliflozin in patients with T2DMand HF had any effect on LV remodeling.Whether the benefits of dapagliflozin in HF are due to remodeling or other mechanisms remains unknown.

UR - http://www.scopus.com/inward/record.url?scp=85085264878&partnerID=8YFLogxK

U2 - 10.2337/dc19-2187

DO - 10.2337/dc19-2187

M3 - Article

C2 - 32245746

SN - 0149-5992

VL - 43

SP - 1356

EP - 1359

JO - Diabetes Care

JF - Diabetes Care

IS - 6

ER -

Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Identifying Novel Opportunities for Translational Research, Precision Medicine and Drug Repurposing in Cardiovascular Disease using Pharmacoepidemiology, Genetic Epidemiology and Bioinformatics

REnal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop DiurEtics in Diabetic Patients with Chronic Heart Failure (RECEDE-CHF)

MetfoRmin and its Effects on Myocardial Dimension and Left Ventricular Hypertrophy in Normotensive Patients with Coronary Artery Disease (MET-REMODEL Trial)

Houston, Graeme

Health Informatics Centre

Cite this

Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Projects

Identifying Novel Opportunities for Translational Research, Precision Medicine and Drug Repurposing in Cardiovascular Disease using Pharmacoepidemiology, Genetic Epidemiology and Bioinformatics

REnal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop DiurEtics in Diabetic Patients with Chronic Heart Failure (RECEDE-CHF)

MetfoRmin and its Effects on Myocardial Dimension and Left Ventricular Hypertrophy in Normotensive Patients with Coronary Artery Disease (MET-REMODEL Trial)

Profiles

Houston, Graeme

Equipment

Health Informatics Centre

Cite this